Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. monthly Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E38.81 EPS (ttm)2.23 Insider Own0.10% Shs Outstand1.48B Perf Week5.58%
Market Cap128.34B Forward P/E9.10 EPS next Y9.52 Insider Trans13.57% Shs Float1.48B Perf Month16.32%
Income3.32B PEG11.53 EPS next Q2.21 Inst Own72.10% Short Float4.30% Perf Quarter37.60%
Sales32.87B P/S3.90 EPS this Y4.80% Inst Trans1.77% Short Ratio7.92 Perf Half Y9.01%
Book/sh-5.55 P/B- EPS next Y6.48% ROA5.60% Target Price92.30 Perf Year-3.38%
Cash/sh7.19 P/C12.05 EPS next 5Y3.37% ROE-39.10% 52W Range62.66 - 94.98 Perf YTD-6.00%
Dividend4.28 P/FCF19.14 EPS past 5Y7.60% ROI21.80% 52W High-8.76% Beta0.94
Dividend %4.94% Quick Ratio1.00 Sales past 5Y11.80% Gross Margin77.00% 52W Low38.30% ATR1.74
Employees30000 Current Ratio1.20 Sales Q/Q3.00% Oper. Margin20.00% RSI (14)80.77 Volatility2.71% 2.11%
OptionableYes Debt/Eq- EPS Q/Q-30.00% Profit Margin9.80% Rel Volume0.72 Prev Close86.44
ShortableYes LT Debt/Eq- EarningsNov 01 BMO Payout191.10% Avg Volume8.01M Price86.66
Recom2.10 SMA208.56% SMA5015.40% SMA20014.80% Volume6,012,601 Change0.25%
Sep-26-19Upgrade Citigroup Neutral → Buy $87 → $90
Aug-20-19Upgrade Piper Jaffray Neutral → Overweight $80
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Apr-29-19Upgrade BMO Capital Markets Underperform → Market Perform
Mar-25-19Downgrade Argus Buy → Hold
Jan-23-19Initiated UBS Neutral $91
Jan-03-19Downgrade BofA/Merrill Buy → Neutral
Dec-26-18Initiated Standpoint Research Buy
Oct-22-18Reiterated SunTrust Buy $157 → $135
Oct-04-18Reiterated BofA/Merrill Buy $107 → $106
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Nov-14-19 06:00AM  Beware of Runs on Bond Funds Barrons.com
05:01AM  AbbVie Sold $30 Billion in Bonds, and Two More Numbers to Know Barrons.com
Nov-13-19 12:03PM  AbbVie Takes on Debt to Buy Allergan GuruFocus.com
10:46AM  AbbVies $30 Billion Bond Sale Was Wall Streets Biggest This Year Barrons.com
09:30AM  Abbott Labs Chooses an Insider to Be Its New CEO Barrons.com
03:52AM  Cash Stashes Dwindle as Markets Crest and Powell Speaks: Market Recon TheStreet.com
Nov-12-19 09:45PM  AbbVie Prices $30 Billion of Senior Unsecured Notes PR Newswire
05:12PM  AbbVie Sells $30 Billion of Bonds to Fund Allergan Acquisition Bloomberg
04:40PM  US Indexes End the Day Higher Tuesday GuruFocus.com
02:11PM  Corporations Pile Into Bond Market as Borrowing Costs Drop Bloomberg
11:15AM  New Positive Data for RINVOQ (upadacitinib) on Signs and Symptoms in Patients with Ankylosing Spondylitis Presented at 2019 ACR/ARP Annual Meeting PR Newswire
08:31AM  The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv Zacks
06:56AM  AbbVie Rises 3% Investing.com
06:46AM  AbbVie sells $30bn of bonds to finance Allergan takeover Financial Times
05:00AM  AbbVie Eyes Up to $28 Billion Bond Sale to Finance Allergan Deal: Report TheStreet.com
Nov-11-19 01:50PM  Top Research Reports for Toyota, Netflix & AbbVie Zacks
01:12PM  Mario Gabelli Continues to Buy AbbVie, Axalta GuruFocus.com
09:03AM  AbbVie Eyes Approval for Imbruvica+Rituxan in First-Line CLL Zacks
Nov-08-19 09:00AM  Psst! Want the Secret to Picking Winning Stocks? Keep Reading. Barrons.com
08:45AM  10 Medical Marijuana Stocks to Cure Your Portfolio InvestorPlace
07:30AM  AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia PR Newswire
05:50AM  AbbVie Rises 3% Investing.com
Nov-07-19 08:41PM  AbbVie Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Allergan Notes PR Newswire
10:49AM  Zacks.com featured highlights include: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard Enterprise and Bristol-Myers Squibb Zacks
10:18AM  AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's new sr. notes; stable outlook Moody's
Nov-06-19 03:06PM  AbbVie Announces Launch of Private Offering of Senior Unsecured Notes PR Newswire
05:11AM  Should You Worry About AbbVie Inc.'s (NYSE:ABBV) CEO Pay Cheque? Simply Wall St.
Nov-05-19 06:16PM  Vanguard Health Care Fund Sells Out of Allergan GuruFocus.com
11:02AM  Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View Zacks
10:48AM  Allergan's Q3 Sales Get A Facelift From Botox; AbbVie Deal On Track Benzinga
10:11AM  The Zacks Analyst Blog Highlights: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard and Bristol-Myers Squibb Zacks
09:00AM  AbbVie Stock Is Poised To Become A Top 5 Pharma But Should You Buy It? Investor's Business Daily
04:40AM  [video]Allergan Tops Q3 Earnings, Bumps 2019 Sales Guidance Amid AbbVie Takeover TheStreet.com
Nov-04-19 01:00PM  Value Biotech ETFs & Stocks to Buy Now Zacks
11:54AM  ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally Zacks
11:20AM  Eaton Vance Worldwide Health Sciences Fund Buys 2 Stocks GuruFocus.com
10:08AM  Top Ranked Income Stocks to Buy for November 4th Zacks
09:10AM  Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y Zacks
09:08AM  Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss Zacks
09:07AM  5 High-Flying Stocks Near 52-Week High That Can Scale Higher Zacks
08:44AM  When Does Market Timing Actually Work? - November 04, 2019 Zacks
08:31AM  AbbVie to Showcase Depth of Immunology Portfolio and Pipeline at the 2019 ACR/ARP Annual Meeting PR Newswire
01:00AM  Rounding Up Big Pharma Earnings Morningstar
Nov-03-19 09:47PM  Edited Transcript of ABBV earnings conference call or presentation 1-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-02-19 11:56AM  Barron's Picks And Pans: AbbVie, Alibaba, Fiat Chrysler, Garmin And More Benzinga
07:00AM  Starbucks, AbbVie, and 4 Others Announce Dividend Hikes Barrons.com
Nov-01-19 07:02PM  5 High-Yield Stocks That Can Keep On Giving Barrons.com
04:21PM  AbbVie Stock Jumps On Strong Quarter As Allergan Takeover Looms Investor's Business Daily
04:21PM  S&P500 and Nasdaq hit new records after October jobs numbers beat expectations MarketWatch
03:24PM  6 Top Stock Trades for Monday: BABA, PINS, CVX InvestorPlace
02:47PM  AbbVie (ABBV) Beats on Q3 Earnings & Sales, Tweaks EPS View Zacks
11:28AM  AbbVie Stock Jumps On Strong Quarter As Allergan Takeover Looms Investor's Business Daily
11:07AM  WIll Allergan (AGN) Beat Estimates This Earnings Season? Zacks
10:55AM  Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates Zacks
10:10AM  AbbVie says multiple parties vying for assets related to Allergan deal approval Reuters
10:00AM  Top Ranked Growth Stocks to Buy for November 1st Zacks
09:33AM  AbbVie Hits Another Home Run, Even as Humira Sales Drop TheStreet.com
09:15AM  Bristol-Myers (BMY) Hits Fresh High: Is There Still Room to Run? Zacks
09:10AM  Should Value Investors Buy AbbVie (ABBV) Stock? Zacks
09:05AM  AbbVie (ABBV) Q3 Earnings and Revenues Beat Estimates Zacks
09:04AM  AbbVie Delivers on Earnings and Raises Forecast Barrons.com
08:46AM  UPDATE 2-AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales Reuters
08:45AM  Is AbbVie (ABBV) a Solid Growth Stock? 3 Reasons to Think " Yes " Zacks
08:12AM  AbbVie Reports Q3 Earnings Beat Benzinga
08:06AM  AbbVie beats earnings expectations and raises outlook, boosts dividend by 10% MarketWatch
07:52AM  AbbVie boosts 2019 profit outlook as Humira helps beat revenue estimates Reuters
07:47AM  AbbVie Reports Third-Quarter 2019 Financial Results PR Newswire
06:13AM  UPDATE 1-Novartis arthritis drug falls short in challenge to global bestseller Reuters
04:08AM  [video]AbbVie Posts Stronger-Than-Expected Earnings, Lifts Forecast TheStreet.com
03:50AM  AbbVie Earnings, Revenue Beat in Q3 Investing.com
Oct-31-19 10:17AM  AbbVie Has Turned to the Upside So Continue to Hold Longs and Raise Sell Stops TheStreet.com
08:45AM  RINVOQ (upadacitinib) Meets Primary and All Ranked Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis PR Newswire
06:30AM  AbbVie Reports Earnings Tomorrow. Heres What to Expect. Barrons.com
Oct-30-19 04:32PM  AbbVie (ABBV) Set to Report Q3 Results: Can Things Turnaround? Zacks
12:17PM  U.S. lobbying for U.K. drug price rise prompts Johnson, Corbyn clash over post-Brexit trade pact MarketWatch
09:15AM  Why AbbVie (ABBV) is a Great Dividend Stock Right Now Zacks
Oct-29-19 05:01PM  McDonald's, AbbVie nab 2019 Chicago Innovation Awards American City Business Journals
09:03AM  AbbVie Launches Let Me Be Clear to Empower People with Psoriasis to Speak Up and Seek Freedom from Their Disease PR Newswire
Oct-28-19 09:31AM  Imbruvica to Offset Humira Woes in AbbVie (ABBV) Q3 Earnings? Zacks
Oct-27-19 11:29AM  Top Marijuana Stocks That Pay Dividends Investopedia
Oct-25-19 12:21PM  And the Winner for the Worst Corporate Deal Is Bayer GuruFocus.com
11:10AM  What's in the Cards for AbbVie (ABBV) This Earnings Season? Zacks
10:30AM  AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth Zacks
10:28AM  Allergan Finance, LLC -- Moody's assigns Baa2 to AbbVie's exchange note offering Moody's
08:11AM  AbbVie Announces Commencement of Exchange Offers and Consent Solicitations for Allergan Notes PR Newswire
Oct-24-19 08:30AM  AbbVie to Present at the Wolfe Research Inaugural Healthcare Conference PR Newswire
08:00AM  AbbVie Announces Collaboration with Cystic Fibrosis Foundation PR Newswire
Oct-23-19 08:00AM  AbbVie's Suzanne Campbell recognized by peers CNW Group
Oct-22-19 12:52PM  Goldman Sachs: 3 High-Yield Dividend Stocks With Growth on the Horizon TipRanks
10:11AM  Biogen (BIIB) Beats on Q3 Earnings, Eyes FDA Nod for Aducanumab Zacks
Oct-21-19 05:45PM  AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know Zacks
01:00PM  CEO Confidence Is Down, Goldman Sachs Says. Look for a Turnaround in 2020. Barrons.com
11:00AM  What's in Store for Healthcare ETFs in Q3 Earnings? Zacks
Oct-18-19 11:52AM  AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review Zacks
10:57AM  Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow Zacks
07:30AM  AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis PR Newswire
Oct-17-19 03:38PM  Why Health Care Stocks Can Rebound Despite 2020 Election Turmoil Investopedia
12:12PM  Novartis' Jakavi Meets Primary Goal in Phase III for GVHD Zacks
10:24AM  The Long Decline in AbbVie Is Over TheStreet.com
08:54AM  Top Ranked Income Stocks to Buy for October 17th Zacks
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; and Cystic Fibrosis Foundation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RICHMOND TIMOTHY J.EVP, Chief HR OfficerSep 27Sale75.0215,5151,163,8730Oct 01 05:52 PM
Schumacher Laura JVice ChairmanSep 16Buy70.4225,0001,760,523164,838Sep 18 04:25 PM
Donoghoe NicholasSVP, Enterprise InnovationAug 29Buy66.197,525498,05713,090Aug 30 04:08 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsAug 16Buy64.4415,5521,002,16965,304Aug 20 04:16 PM
AUSTIN ROXANNE SDirectorAug 01Buy65.6625,0001,641,400117,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 31Buy66.0230,0001,980,69092,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 30Buy66.3510,000663,50062,114Jul 31 04:46 PM
Gosebruch Henry OEVP, Chief Strategy OfficerJul 29Buy67.2830,0002,018,38575,763Jul 31 04:46 PM
AUSTIN ROXANNE SDirectorJun 26Buy67.5011,500776,25052,114Jun 28 04:47 PM
CHASE WILLIAM JEVP, Finance & AdministrationJun 26Buy67.3030,4002,045,920169,552Jun 28 04:47 PM
RAPP EDWARD JDirectorJun 26Buy67.307,500504,75030,662Jun 28 04:48 PM
Durkin Brian LVP, ControllerMar 25Sale79.6947537,8539,121Mar 25 04:34 PM
Schumacher Laura JVice ChairmanMar 14Sale80.0025,0002,000,000139,838Mar 15 05:53 PM
SALEKI-GERHARDT AZITAEVP, OperationsMar 05Sale79.0315,7971,248,48093,312Mar 06 05:03 PM
Schumacher Laura JVice ChairmanDec 28Sale90.0025,0002,250,000134,322Jan 02 04:49 PM
CHASE WILLIAM JEVP, Finance & AdministrationDec 12Sale90.0060,0005,400,000104,863Dec 14 05:12 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 11Sale88.7516,8501,495,438286,203Dec 13 04:56 PM
Schumacher Laura JExecutive Vice PresidentDec 04Option Exercise51.4294,1404,840,679192,398Dec 07 05:15 PM
Schumacher Laura JExecutive Vice PresidentDec 04Sale93.5894,1408,809,55298,258Dec 07 05:15 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 29Sale90.1042,4503,824,94030,350Nov 30 05:22 PM